National Institute of Neurological Disorders and Stroke (NINDS)
The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA) intend to publish a Funding Opportunity Announcement (FOA) to solicit applications for basic and translational research on the impact of the microbiome gut-brain axis on Alzheimer’s Disease Related Dementias (ADRD). While there is growing evidence that the microbiome is an important factor that contributes to overall health and a variety of diseases and disorders, the role of intestinal microbiota dysfunction in specific ADRDs has not been adequately addressed. Furthermore, there is a need for more engagement of the ADRD research community to better understand the mechanistic relationship between the gut-brain axis and dementia-related diseases. This FOA will support mechanistic and early translational research focused on a more rigorous in-depth examination of the potential interactions between the gut microbiome and genetic and non-genetic molecular targets that influence ADRD. It is expected that these studies will address the clinical relevance of the gut microbiome on disease initiation, progression, or modification that will lead ultimately to better therapeutic interventions.
This Notice is being provided to allow potential applicants sufficient time to develop integrated multidisciplinary collaborations and responsive projects.
The FOA is expected to be published in Summer 2022 with an expected application due date in Fall 2022.
This FOA will utilize the R01 (Clinical Trials Not Allowed) activity code.
The proposed FOA will solicit team science between ADRD researchers that have deep expertise in basic, translational, and clinical research, and scientists with expertise in intestinal and mucosal physiology, immunology, and metabolomics within the gut microbiome, and the potential use of pre- and probiotics as an intervention. The FOA will support research on ADRDs including Frontotemporal Degeneration, Lewy Body Dementia, Vascular Contributions to cognitive Impairment and Dementia, and Mixed Etiology Dementias. The scope of the FOA will include mechanistic, translational, and human subjects (clinical trials not allowed) research. Several examples of projects include, but are not limited to, mechanistic research on the relationship between microbiota within human samples and ADRD, in vitro and in vivo animal models of ADRD that incorporate modification of the gut microbiome, and pre-clinical testing of probiotics and other interventions. Outcomes include a better understanding of the potential influence of the gut microbiome on ADRDs and more engagement of the ADRD research community within this field of study.
Applications are not being solicited at this time.
Please direct all inquiries to:
David A. Jett, Ph.D.